Feature | Artificial Intelligence | June 10, 2021

AI Collaboration is Key to Unlock its Power in Cardiac Care

GE is integrating artificial intelligence into most of its imaging and information technology software. AI can aid fast critical care decision making. Above left is the vScan Air wireless point-of-care ultrasound system. It integrates AI for immediate, automated assessment of a patient's ejection fraction, right.

GE is integrating artificial intelligence into most of its imaging and information technology software. AI can aid fast critical care decision making. Above left is the vScan Air wireless point-of-care ultrasound system. It integrates AI for immediate, automated assessment of a patient's ejection fraction, right.

The digital transformation of healthcare is underway, but it will advance further and faster if key stakeholders work together. That is the idea behind the Applied Health Innovation Consortium (AHIC) led by the American College of Cardiology (ACC). Together with researchers, clinicians, patient advocates and technology developers, the ACC seeks to develop a roadmap for artificial intelligence (AI) that will enable clinicians to predict and address an individual patient’s needs with greater precision, ideally before the patient gets sick.

Artificial Intelligence Might Better Identify and Manage AFib Patients

For example, one complex problem that cardiologists face regularly is the cardiac arrhythmia atrial fibrillation (AF). According to the Centers for Disease Control, an estimated 12.1 million people in the United States will have AF in 2030.[1] The American Heart Association says patients with AF are five times more likely to have a stroke, three times more likely to suffer heart failure and are hospitalized twice as often as patients without AF.[2] In addition to its clinical implications, AF costs the United States health care system an estimated $26 billion each year.[2]

While strides have been made to combat AF, the magnitude and complexity of the problem demands a new approach to maximize value from the mountains of clinical data we now possess to diagnose and treat patients with speed, accuracy, and efficiency. Could AI be the answer? Jonathan Lindner, M.D., the M. Lowell Edwards Professor of Cardiology at Oregon Health and Science University, believes so.

“Having an AI algorithm that is extremely well vetted and that has data behind it in terms of being able to not only help clinicians predict these diseases, but also predict who is likely to respond to certain therapies, would allow us to essentially go into a patient’s room with much more confidence and tell them that they are highly likely to either benefit from a certain therapy or not,” Lindner said.

While the prospect of being able to better predict and possibly prevent disease before it takes hold is both exciting and transformational, there are barriers to integrating AI with clinical medicine.

Successfully Applying AI to Digital Cardiac Healthcare

According to John Rumsfeld, M.D.,the chief innovation officer and chief science and quality officer at the ACC, “The promise of AI for healthcare is that we could be more efficient, improve clinician well-being and patient engagement, and improve health and health outcomes if it’s done correctly.”

The ACC has long anticipated the digital transformation in healthcare – or shifting the focus of care to virtual care and remote monitoring – and is committed to helping facilitate and execute an ongoing innovation strategy. Rumsfeld said the keys to AI being successfully applied to digital healthcare are high-quality data, clinical use cases, effective integration into workflow and training future generations that this is the way we deliver care—and that we can move further faster to deliver trust in the form of evidence and standards if we collaborate cross-functionally.

Rumsfeld lauds strong industry participation, such as GE Healthcare’s involvement with the AHIC.

“If we’re going to have tools like AI make a fundamental difference in the way we deliver care, no organization can do that alone. We need collaborators who share the same vision and bring different strengths to the table. GE has been right at the forefront of helping the ACC reimagine healthcare delivery,” he said.

Currently GE Healthcare’s Edison platform forms the technological basis for the company’s many AI offerings that are poised to become an integral part of the advanced cardiac technology used by clinicians in the diagnosis and treatment of more than 145 million hearts each year.

Rumsfeld envisions a future in which clinicians are using AI predictive algorithms to highlight people who may be at such a high risk for developing complications for which preemptive action is recommended.

“Today, we’ll look at a patient and say they have moderate aortic stenosis, but one such patient may stay in that state forever and never need a valve intervention while another may have a digital phenotype that suggests they’re going to have rapid progression and need earlier intervention. The individual human eye isn’t going to be able to interpret that based on images alone. This is where AI can make us better at what we do,” Rumsfeld exlained. “AI won’t just interpret the image, but it actually can see patterns in the imaging that will make us better at diagnosis and better at predicting future course of care and outcomes for patients.”

 

Related Artificial Intelligence in Cardiology Content:

VIDEO: ACC Efforts to Advance Evidence-based Implementation of AI in Cardiovascular Care — Interview with John Rumsfeld, M.D.

GE Healthcare and the ACC Join Forces to Advance AI in Cardiac Care

Artificial Intelligence Applications in Cardiology

Vendors and ACC Collaborate With Consumer Technology Association to Help Clinicians and Patients Understand Cardiovascular Devices

Applications for Artificial Intelligence in Cardiovascular Imaging

VIDEO: Artificial Intelligence Applications for Cardiology — Interview with Anthony Chang, M.D.

 

References:

1. Salim S. Virani, Alvaro Alonso, Hugo J. Aparicio, et al.Heart Disease and Stroke Statistics—2021 Update. A Report From the American Heart Association. Circulation. Vol. 143, No. 8, February 23, 2021. https://doi.org/10.1161/CIR.0000000000000950Circulation. 2021;143:e254–e743.

2. Michael H. Kim, Stephen S. Johnston, Bong-Chul Chu, Mehul R. Dalal, and Kathy L. Schulman.Estimation of Total Incremental Health Care Costs in Patients With Atrial Fibrillation in the United States. Circulation: Cardiovascular Quality and Outcomes. 2011;4:313–320. May 2011, Vol 4, Issue 31. https://doi.org/10.1161/CIRCOUTCOMES.110.958165.

 

 

 

Related Content

Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no differences is therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI.

Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no difference if therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI in STEMI with multi-vessel disease.

Feature | ACC | June 08, 2021 | By Dave Fornell, Editor
Here are the top 10 takeaways from the late-breaking studies on cardiovascular technologies presented at the 2021 ...
AMERICAN COLLEGE OF CARDIOLOGY (ACC) Late-breaking clinical trial study presentations at ACC.21. @ACC21 @ACC2021
Feature | ACC | May 18, 2021 | Dave Fornell, Editor
The latest cardiology practice-changing scientific breakthrough, late-breaking study presentations have been announce
To help monitor the health of ACC 2021 in-person attendees for signs of COVID infection, the meeting will use BioIntelliSense's wearable BioButton continuous wireless temperature and vital signs monitoring. The wearable monitor is the size of a coin and is disposable.

To help monitor the health of ACC 2021 in-person attendees for signs of COVID infection, the meeting will use BioIntelliSense's wearable BioButton continuous wireless temperature and vital signs monitoring. The wearable monitor is the size of a coin and is disposable.

News | ACC | February 09, 2021 | By Dave Fornell, Editor
UPDATE Feb 22, 2021 — ...
The American College of Cardiology (ACC) released a list of the latest practice-changing presentations at the ACC.20 annual meeting March 28-30, 2020, in Chicago. This includes five late-breaking clinical trial (LBCT) sessions and three featured clinical research sessions. There also are two LBCT deep-dive sessions where the experts will break down the hottest trials and attendees can find out what the impact might be on the practice of cardiology and patients.
Feature | ACC | April 09, 2020 | Dave Fornell, Editor
Here is the list of American College of Cardiology (ACC) practice-
ACC Cancels 2020 Conference Amid Coronavirus Concerns. #COVID19 #coronavirus #2019nCoV
Feature | ACC | March 09, 2020 | Dave Fornell, Editor
March 9, 2020 — Less than week after the American College of Cardiolog...
American College of Cardiology Names Douglas Drachman Next Annual Scientific Session Vice Chair

Image courtesy of Massachusetts General Hospital

News | ACC | October 08, 2019
Douglas Drachman, M.D., FACC, has been selected as the next vice chair of the American College of Cardiology’s (ACC)...
SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions. FFR in the cath lab.

SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions.

Feature | ACC | March 27, 2019 | Greg Freiherr, Contributing Editor
The fingerprints of value-added medicine were all over products and works-in-progress on the exhibit floor of the a

The opening late-breaking trial at ACC 2019 is the Apple Heart Study, a large-scale, app-based study to identify atrial fibrillation using a smartwatch. Earlier, smaller trials showed this approach might be used in a population health application to proactively identify AFib patients earlier.

Feature | ACC | March 19, 2019
The American College of Cardiology (ACC) released a list of the late
A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle